Kilitch Drugs (India) Limited, a BSE- and NSE-listed pharmaceutical company specializing in parenterals, injectables, oral solids, and effervescent formulations, has announced a rights issue to raise approximately INR 49.92 crore.

At its recent board meeting, the company approved the issuance of 1,398,463 fully paid-up equity shares at INR 357 per share (face value INR 10 and premium of INR 347). The entitlement ratio for eligible shareholders is 2 rights equity shares for every 23 fully paid equity shares held.

The issue opens on Wednesday, July 23, 2025, and will close on Thursday, August 21, 2025. The last date for market renunciation is Monday, August 18, 2025.

The funds raised will be deployed to strengthen the balance sheet, fuel growth initiatives including the greenfield manufacturing facility in Pen, Maharashtra, and for general corporate purposes.

Mukund Prataprai Mehta, Managing Director of Kilitch Drugs, said, “This rights issue offers our shareholders a compelling opportunity to be part of our future growth. The capital will help us expand our product offerings, improve operational efficiencies, and strengthen our position as we scale into regulated markets with the Pen facility.”

Established in 1992, Kilitch Drugs has manufacturing units in Mumbai and Ethiopia and is currently setting up a US FDA-compliant greenfield facility in Pen, Maharashtra. The facility will focus on injectables, ophthalmics, oral solids, and nutraceuticals, aligning with global regulatory requirements.